Immunomedicor Incorportated
Vision About Us Products Research Contact Us


 


Our Vision and Mission

At Immunomedicor we are researching and developing drug candidates to sustain, improve and prolong human life. Our near term vision is to develop and license non-toxic and non-homeopathic Cancer and HIV treatment drug candidates which have very few, if any, side effects.

Our mission is to not take away from the human condition, but to restore life to the best state it can be. We intend to be one of the major factors in a holistic approach to health.

Please see our research and products sections to learn more about our value.


Our Revolutionary Business Model

Not only is our technology cutting edge, but also we are a company with a revolutionary business model for success. Our company is a strong part of our employee’s quality of life and career success. For example, most employees will be equipped with a mobile laptop with a built in video camera so that they can communicate instantly from whatever location they may be working from. If you are highly self motivated, then our model will enable you to achieve your highest career goals. Our team has a strong mutual respect for each other and for how the company so seamlessly fits into our employees lives. Please contact us by visiting our Contact Us section for further details on a potential Immunomedicor career.


 

 Immunomedicor News
07/08/08
After nearly 12 years of research and development, Immunomedicor begins to further commercialize a novel line of drugs for various Auto Immune System disorders.

07/23/08
Immunomedicor announces its vision at the first anual Crab Boil in Washington, DC.

08/23/08
Immunomedicor begins work on business plan towards funding development of potential drug candidates.

09/07/08
Immunomedicor begins research on the development of IM-039-MAB-CAN, a non-toxic drug to be used in the treatment of various types of Cancer.

11/24/08
Immunomedicor public web site goes live.

01/24/09
Immunomedicor ribbon cutting ceremony scheduled to take place on Jan 24, 2009 in Washington, DC.

02/28/09
Immunomedicor releases news update on Immucore molecule status in public press release and web video.

04/25/09
Immunomedicor releases product information in web video.

07/18/09
Immunomedicor forms strategic alliances with leading biotech industry and education partners.

07/15/10
Immunomedicor begins next round of fundraising for IM-039-MAB-MML. John Kruebbe, the new CEO and CTO works to recruit new scientists to the company.

07/22/10
Immunomedicor recruits a new science advisor to the board of directors, Chun-Hsien Huang, and initial work begins on patenting and manufacturing Imucore for further pre-clinical trials.

 

 

 

 

 

 


©2008 - 2010 Immunomedicor, Incorporated ProductsContact UsResearchAbout UsVision